GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Abingdon Health PLC (OTCPK:ABDXF) » Definitions » EBITDA Margin %

Abingdon Health (Abingdon Health) EBITDA Margin % : -37.40% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Abingdon Health EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Abingdon Health's EBITDA for the six months ended in Dec. 2023 was $-1.14 Mil. Abingdon Health's Revenue for the six months ended in Dec. 2023 was $3.05 Mil. Therefore, Abingdon Health's EBITDA margin for the quarter that ended in Dec. 2023 was -37.40%.


Abingdon Health EBITDA Margin % Historical Data

The historical data trend for Abingdon Health's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abingdon Health EBITDA Margin % Chart

Abingdon Health Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBITDA Margin %
Get a 7-Day Free Trial -48.44 15.48 -51.39 -701.55 -69.49

Abingdon Health Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -296.47 -1,311.56 -184.11 -26.10 -37.40

Competitive Comparison of Abingdon Health's EBITDA Margin %

For the Diagnostics & Research subindustry, Abingdon Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abingdon Health's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Abingdon Health's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Abingdon Health's EBITDA Margin % falls into.



Abingdon Health EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Abingdon Health's EBITDA Margin % for the fiscal year that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2023 )/Revenue (A: Jun. 2023 )
=-3.549/5.107
=-69.49 %

Abingdon Health's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-1.141/3.051
=-37.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abingdon Health  (OTCPK:ABDXF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Abingdon Health EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Abingdon Health's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Abingdon Health (Abingdon Health) Business Description

Traded in Other Exchanges
Address
York Biotech Campus, Sand Hutton, York, GBR, YO41 1LZ
Abingdon Health PLC is a technology-enabled lateral flow diagnostics company. It provides rapid testing solutions to clients in healthcare and other industries. The firm's product ABC-19 is an antibody test for Covid-19 , and also produces tests covering areas such as self-test HIV, equine infection, human fertility, etc. Business operating segments includes; Contract Development comprises development work for third parties. Contract Manufacturing comprises contract development and manufacturing activities. Product Sales comprises the sale of ABC-19, Pocket Diagnostic products, PCRD tests and antibodies for research use. Key revenue comes from Contract Development segment. Geographically it operates and earns revenue from the UK, USA and Canada, Europe and the rest of the world.

Abingdon Health (Abingdon Health) Headlines

From GuruFocus

AbC-19� Rapid Test Available for Purchase by Healthcare Professionals

By Business Wire Business Wire 02-16-2021